2022-24273. Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium

Notice is hereby given that, on October 6, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”), Medical CBRN Defense Consortium (“MCDC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Adaptive Phage Therapeutics, Inc., Gaithersburg, MD; Amentum Services, Inc., Germantown, MD; Benevira, Inc., New York, NY; Domenix Corporation, Chantilly, VA; International Business Machines Corporation, Yorktown Heights, NY; Rajant Corporation, Malvern, PA; SGSD Partners LLC, Washington, DC; The Washington University, Saint Louis, MO; and Zymeron Corporation, Durham, NC have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership.

On November 13, 2015, MCDC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on January 6, 2016 (81 FR 513).

The last notification was filed with the Department on July 6, 2022. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on August 30, 2022 (87 FR 53005).

Catherine Reilly,

Counsel for Civil Operations, Antitrust Division.